B
Beam Therapeutics Inc. (BEAM)
NMS – Real vaqt narxi. Valyuta: USD
31.58
-0.17 (-0.54%)
Yopilishda: May 12, 2026, 4:00 PM EDT
31.92
+0.34 (1.08%)
Bozor oldidan: May 13, 2026, 9:00 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
31.58
-0.17 (-0.54%)
Yopilishda: May 12, 2026, 4:00 PM EDT
31.92
+0.34 (1.08%)
Bozor oldidan: May 13, 2026, 9:00 AM EDT
Beam Therapeutics Inc., biotexnologiya kompaniyasi, Qo'shma Shtatlarda jiddiy kasalliklardan aziyat chekayotgan bemorlar uchun aniq genetik dorilarni ishlab chiqish bilan shug'ullanadi. Gematologiya va genetik kasalliklar portfelidagi dasturlari orasida Ristoglogene autogetemcel, talassemiya kasalligini davolash uchun bemorga moslashtirilgan, avtologik gematopoyetik ildiz hujayrasi (HSC) terapiyasi; og'ir alfa-1 antitripsin etishmovchiligini davolash uchun jigarga yo'naltirilgan lipidli nanozarra (LNP) BEAM-302; fenilketonuriyani davolash uchun jigarga yo'naltirilgan LNP BEAM-304; va 1a turdagi glyukogen saqlash kasalligini davolash uchun jigarga yo'naltirilgan LNP formulasi BEAM-301 mavjud. Kompaniya, shuningdek, antitelaga asoslangan konditsionerlikni ko'plab genetik tahrirlangan HSClar bilan birlashtiradigan ESCAPE platformasini ishlab chiqadi. Bundan tashqari, u ESCAPE-ni faollashtiradigan CD117 ga qarshi monoklonal antitelasi BEAM-103 ni ishlab chiqadi. Kompaniya Pfizer Inc. bilan tadqiqot hamkorlik shartnomasiga ega bo'lib, unda jigarning, mushaklarning va markaziy asab tizimining kam uchraydigan genetik kasalliklari uchun in vivo asosiy tahrir dasturlari; Verve Therapeutics, Inc. bilan yurak-qon tomir kasalliklarini davolash bo'yicha; va Orbital Therapeutics bilan inson kasalliklarini oldini olish, davolash yoki tashxislash uchun RNKni loyihalash bo'yicha hamkorlik qiladi. Beam Therapeutics Inc. 2017 yilda tashkil etilgan va Massachusets shtatining Kembrij shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Amy Simon M.D. | Chief Medical Officer |
| Dr. Christine P. Bellon J.D., Ph.D. | Chief Legal Officer & Corporate Secretary |
| Dr. David R. Liu Ph.D. | Co-Founder |
| Dr. Feng Zhang Ph.D. | Co-Founder |
| Dr. Giuseppe Ciaramella Ph.D. | President |
| Dr. J. Keith Joung M.D., Ph.D. | Co-Founder |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | beam-20260507.htm |
| 2026-05-07 | 10-Q | beam-20260331.htm |
| 2026-04-17 | DEFA14A | defa14a_2026.htm |
| 2026-04-17 | ARS | ars_2026.pdf |
| 2026-03-05 | 8-K | beam-20260302.htm |
| 2026-02-24 | S-8 | beam-20260224.htm |
| 2026-02-24 | 10-K | beam-20251231.htm |
| 2026-02-12 | 8-K | beam-20260209.htm |
| 2026-02-05 | 8-K | beam-20260131.htm |
| 2026-01-12 | 8-K | beam-20260111.htm |
| Dr. Manmohan Singh Ph.D. | Chief Technology Officer |
| Mr. John M. Evans M.B.A. | CEO & Director |
| Mr. Sravan Kumar Emany | Chief Financial Officer |
| Ms. Bethany J. Cavanagh | Senior VP of Finance, Treasurer & Principal Accounting Officer |